Here's the Biggest Challenge Pfizer Faces Right Now
It's fair to say Pfizer (NYSE: PFE) has become a coronavirus vaccine powerhouse. The big pharma company landed the first Emergency Use Authorization (EUA) for a COVID-19 vaccine in December. And it has managed to stay ahead of rivals so far. It's fully vaccinated more than 35 million people in the U.S. That's compared to 30 million for Moderna and 6 million for Johnson & Johnson.
Pfizer and partner BioNTech expect the vaccine to generate about $15 billion in revenue this year. Now, they're going after a broader audience that could boost sales further in the years to come. Pfizer just requested an EUA for use of its vaccine in individuals ages 12 through 15. That's after reporting positive trial data. The current authorization covers people ages 16 and older. All of this sounds great. But, if the U.S. Food and Drug Administration (FDA) gives Pfizer the nod, there's one big challenge the company faces.
Image source: Getty Images.
Source Fool.com
